Fifty patients with moderate or severe bronchitis were randomly allocated into groups receiving orally either 1000 mg amoxycillin twice daily or 750 mg three times daily. Overall cure rates (both 92%) and the incidence of side-effects (4% and 8%, respectively) were similar in both groups. A twice daily regimen, therefore, seems to be as effective as conventional treatment and has the advantage of being more convenient for the patient
Get full access to this article
View all access options for this article.
References
1.
BerganTCarisenB: Bacterial kill rates of amoxycillin and ampicillin at exponentially diminishing concentrations simulating in vitro conditions. Infection1980; 8 (suppl 1): 103–108.
2.
BoonRJComberKR: Bactericidal effects of sodium amoxycillin and sodium ampicillin against Gram-negative bacilli in vitro and in vitro and the morphological response in vivo. Curr Ther Res1981: 30: 981–994.
3.
HunterPARolinsonGNWittingDA: Comparative activity of amoxicillin and ampicillin in an experimental bacterial infection in mice. Antimicrob Agents Chemother1973; 4: 285–293.
4.
GrunbergECleelandRBeskidG: In vivo activity of amoxicillin and ampicillin against Gram-positive bacteria: results of prophylactic studies. J Infect Dis1978; 138: 872–876.
5.
KlausUHenningerWJacobiP: Bacterial elimination and therapeutic effectiveness under different schedules of amoxycillin administration. Chemotherapy1981; 27: 200–208.
6.
RolinsonGNMacDonaldACWilsonDA: Bactericidal action of β-lactam antibiotics on Escherichia coli with particular reference to ampicillin and amoxycillin. J Antimicrob Chemother1977; 3: 541–553.
7.
ComberKROsborneCDSutherlandR: Comparative effects of amoxicillin and ampicillin in the treatment of experimental mouse infections. Antimicrob Agents Chemother1975; 7: 179–185.
8.
Medical Research Council Committee on the Aetiology of Chronic Bronchitis: Definition and classification of chronic bronchitis for clinical and epidemiological purposes. Lancet1965; i: 775–779.
9.
PinesA: Successful treatment of respiratory tract infections in patients with chronic respiratory disease—how to make objective conclusions. J Antimicrob Chemother1982; 9: 165–167.
10.
MulderJGoslingsWROvan der PlasMC: Studies on the treatment with antibacterial drugs of acute and chronic mucopurulent bronchitis caused by Haemophilus influenzae. Acta Med Scand1952; 111: 32–49.
11.
Deutsche Gesellschaft für Hygiene und Mikrobiologie: Kommissionen für Verfahrensrichtlinien (Leiter: Burkhadt F.) Die mikrobiologische Diagnose von Infektionen der tieferen Atemwege und der Lunge. Zentralbl Bakteriol Mikrobiol Hyg (A)1980; 248: 162–176.
12.
KnotheH: In vrtro-Aktivität von Amoxicillin. Adv Clin Pharmacol1974; 7: 16–19.
13.
RenkonenOV: Antibacterial activity of nine oral antibiotics against Streptococcus pneumoniae, Haemophilus influenzae and Branhamella catarrhalis. Scand J Infect Dis1983; 39 (suppl): 106–108.
14.
SutherlandRCroydonEAPRobinsonGN: Amoxicillin: a new semisynthetic penicillin. Br Med J1972; 3: 13–16.
15.
YourassowskyESchoutensEVanderlindenMP: Susceptibility of Haemophilus to antibiotics: present status. Infection1975; 3: 15–18.
16.
IngoldA: Sputum and serum levels of amoxycillin in chronic bronchial infections. Br J Dis Chest1975; 69: 211–216.
17.
MayJRIngoldH: Amoxycillin in the treatment of lower respiratory infections. Adv Clin Pharmacol1974; 7: 85–90.
18.
CristianoPParadisiF: Studio clinico sul-l'impiego di amoxicillina a differenti dosaggi nella patologia broncopulmonare. Clin Ter1982; 102: 575–582.
19.
DaschnerFDBehreUDalhoffA: Prospective clinical trial on the efficacy of amoxycillin administered twice or four times daily in children with respiratory tract infections. J Int Med Res1981; 9: 274–276.
20.
GermoutyJ: Utilisation de l'amoxicilline en pneumo-physiologie. Gaz Med Fr1975; 82: 1833–1837.
21.
ColePJRobertsDEDaviesSF: A simple oral antimicrobial regimen effective in severe chronic bronchial suppuration associated with culturable Haemophilus influenzae. J Antimicrob Chemother1983; 11: 109–113.
